Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 12c
November 14, 2022 7:09 AM ESTViridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($0.86), $0.12 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $303.33 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
... More